Unbound MEDLINE

Co-solvent solubilization of some poorly-soluble antidiabetic drugs. Pharmaceutical development and technology [Pharm Dev Technol] Journal article

 
TitleCo-solvent solubilization of some poorly-soluble antidiabetic drugs.
Author(s)Seedher N, Kanojia M 
InstitutionDepartment of Chemistry, Panjab University, Chandigarh, India.
SourcePharm Dev Technol 2009; 14(2):185-92.
AbstractCo-solvent solubilization approach has been used to enhance the solubility of seven antidiabetic drugs: gliclazide, glyburide, glipizide, glimepiride, repaglinide, pioglitazone, and roziglitazone. Solubility in water, phosphate buffer (pH 7.4), six co-solvent solutions prepared in water as well as phosphate buffer (pH 7.4) and pH-solubility profile of various drugs have been determined at 25 degrees C. Aqueous solubility of various drugs was found to be less than 0.04 mg/mL. Solubility of gliclazide, glipizide and repaglinide increased by 3-6 times by using phosphate buffer (pH 7.4) as solvent. Solubility enhancement by pH modification was not sufficient. Significant enhancement in solubility could be achieved by the use of co-solvents. The combined effect of co-solvent and buffer was synergistic and enormous increase in solubility of sulfonylureas and repaglinide could be achieved. In the case of glitazones, however, co-solvent alone caused significant enhancement; the presence of buffer had negative effect on the solubilization potential of the co-solvents. Up to 763, 316, 153, 524, 297, 792 and 513 times increase in solubility could be achieved in the case of gliclazide, glyburide, glimepiride, glipizide, repaglinide, pioglitazone and rosiglitazone, respectively.
Languageeng
Pub Type(s)Journal Article
PubMed ID19519190
  
Advertise on this site.